Advances and challenges of sonodynamic nanomedicines for deep seated tumor therapy

Sonodynamic therapy (SDT) has become a promising, noninvasive treatment modality with deep tissue penetration and precise controllability, offering a new approach for cancer treatment. Nanotechnology improves stability, targeting ability, and therapeutic efficiency of sonosensitizers in deep-seated tumors. This review discusses recent advances in sonodynamic nanomedicines for treating pancreatic, hepatic, and colorectal cancers, focusing on design strategies and mechanisms of metal-based, nonmetal-based, and hybrid nanosystems. Current challenges such as limited reactive oxygen species (ROS) generation, insufficient tumor targeting, hypoxia tolerance, and biosafety concerns are discussed. Future perspectives on multimodal combination therapy, stimuli-responsive nanocarriers, and clinical translation are also highlighted. This review aims to provide insights into the rational design and clinical development of SDT-based nanomedicines for deep-seated tumors.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-03-28
DOI
https://doi.org/10.1007/s12672-026-04563-7
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advances and challenges of sonodynamic nanomedicines for deep seated tumor therapy

Jinlong Zhao, Yongxiang Zhao
Discover Oncology
Nanoplatforms for cancer theranostics
article

Advances and challenges of sonodynamic nanomedicines for deep seated tumor therapy

Jinlong Zhao, Yongxiang Zhao
article en

Abstract

Sonodynamic therapy (SDT) has become a promising, noninvasive treatment modality with deep tissue penetration and precise controllability, offering a new approach for cancer treatment. Nanotechnology improves stability, targeting ability, and therapeutic efficiency of sonosensitizers in deep-seated tumors. This review discusses recent advances in sonodynamic nanomedicines for treating pancreatic, hepatic, and colorectal cancers, focusing on design strategies and mechanisms of metal-based, nonmetal-based, and hybrid nanosystems. Current challenges such as limited reactive oxygen species (ROS) generation, insufficient tumor targeting, hypoxia tolerance, and biosafety concerns are discussed. Future perspectives on multimodal combination therapy, stimuli-responsive nanocarriers, and clinical translation are also highlighted. This review aims to provide insights into the rational design and clinical development of SDT-based nanomedicines for deep-seated tumors.

Discover Oncology
Guangxi Medical University (CN), Theranostics (New Zealand) (NZ), First Affiliated Hospital of GuangXi Medical University (CN)
Good health and well-being
Openalex Percentile: Top 4%
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.